WuXi Biologics Sets 2050 Net-Zero Target, SBTi Approves Emission Reduction Goals
WuXi Biologics (Cayman) Inc., a global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the approval of its near-term and net-zero greenhouse gas emissions reduction targets by the Science Based Targets initiative (SBTi). The company aims to achieve net-zero emissions across its value chain by 2050, aligning with the 1.5°C mitigation pathways. WuXi Biologics' integrated strategy includes measurable targets for emissions reduction, with its efforts recognized by several organizations, including an MSCI AAA Rating, EcoVadis Platinum Medal, and listing in the Dow Jones Sustainability Indices. The company is also a participant in the United Nations Global Compact and Pharmaceutical Supply Chain Initiative.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN61029) on August 28, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。